Clyde Biosciences Demonstrates Superiority Over MEA

Clyde Biosciences is delighted to announce it has demonstrated superiority over the legacy MEA system in the recent international CiPA study. Initiated by the FDA and by the Health and Environment Sciences Institute, the CiPA study pitted Clyde Biosciences’ CellOPTIQ system against the established micro-electrode array. The results of the study confirmed that Clyde Biosciences’ […]

Read More
Ian Whalley
Clyde Biosciences Nominated for Top Award

The Clyde Biosciences team are delighted to have been shortlisted for an award in February’s Scottish Life Sciences Awards. One of three finalists in the Innovative Collaboration award, Clyde has been recognised for its contribution to a global initiative designed to improve the way drugs are assessed for cardiac safety. The initiative, known as CiPA […]

Read More
Ian Whalley
Clyde Recognised as Leading Innovator

Clyde Biosciences has been recognised in The Scotsman newspaper (December 1, 2017) as a leading innovator in Scottish life sciences. Alongside other Scottish companies, Clyde was noted for its recent project with AstraZeneca examining the effects of certain drug compounds on cardiac cells. Clyde’s unique optical cell function assay service provides information to biotech and […]

Read More
Ian Whalley
Clyde Biosciences SPS Poster Downloads

Highlights Clyde Biosciences were delighted to present a total of four posters at the recent SPS meeting in Berlin, representing collobarations with major pharmaceutical companies. The posters showed: The influence of fibroblast co-culture and 3D structures on cardiac action potentials of human stem cell derived cardiomyocytes (Collaboration with Abbvie) AbbVie SPS FINAL Measurements of voltage, intracellular […]

Read More
Ian Whalley
SPS 2017 Posters

Clyde Biosciences Presents Four Posters at SPS 2017 Highlights Clyde Biosciences were delighted to present a total of four posters at the recent SPS meeting in Berlin, representing collobarations with major pharmaceutical companies. The posters showed: The influence of fibroblast co-culture and 3D structures on cardiac action potentials of human stem cell derived cardiomyocytes (Collaboration […]

Read More
Ian Whalley
Groundbreaking Research Into Kinases Using CellOPTIQ From Clyde Biosciences

Recent Publication Highlights Flexibility and Power of Clyde’s CellOPTIQ® Assay Highlights Collaboration with AZ on kinase inhibitor induced cardiotoxicity Understanding E-C coupling is essential in kinase research CellOPTIQ® is the only single mechanistic screen providing insight into E-C coupling mechanism Observing the interplay between voltage, calcium transient and contractility is vital and is only available […]

Read More
Ian Whalley
New Website

Welcome to our new site – Clyde Biosciences is delighted to launch our new website. Have a good look around and please get in touch with feedback or inquiries.

Read More
Ian Whalley
Clyde Biosciences Autumn Business Update

Clyde Biosciences Autumn Business Update Highlights CiPA 28 study finished and data submitted weeks ahead of schedule New CellOPTIQ®-X contractility assay launched New Heart Failure model launched Clyde Biosciences today announces progress in its autumn business update. The company reports that in the last three months it has completed work on a number of important […]

Read More
Ian Whalley
Clyde Launches New Contractility Service – CellOPTIQ®-X

NEWHOUSE – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma clients. CellOPTIQ®-X represents a revolution in contractility assays, offering: Early detection of contractility toxicities Higher throughput, cost-effective solution Reduction in animal requirements Accurate prediction of the human response Reduction in later stage attrition Heart cell […]

Read More
Ian Whalley
Clyde Appoints New Chair

Clyde Biosciences is delighted to announce the appointment of Alan Johnston to the post of Chair. Alan brings a wealth of CRO experience to Clyde. He spent some 30 years with Inveresk Research (subsequently Charles River Laboratories) in Edinburgh, Alan had several Senior Management posts within Inversek and had responsibility for Commercial staff. He is now Trustee […]

Read More
Ian Whalley
Clyde Biosciences Closes Series A Investment

Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd. Clyde Biosciences, a spin-out company from the University of Glasgow, […]

Read More
Ian Whalley